

BD FACSVia™ System

Designed for rapid detection of HLA-B27 antigen expression

An innovative system that provides reliability and consistency for the detection of HLA-B27




With the BD FACSVia™ system, clinical laboratories can obtain accurate and consistent results for the rapid detection of HLA-B27 antigen expression in erythrocyte-lysed whole blood, that can be used with other clinical findings to support diagnose.

- BD™ HLA-B27 reagent kit
- Intuitive BD FACSVia™ clinical software with HLA-B27 predefined templates to ensure reproducible and consistent results
- Automated instrument setup for predictable and reproducible sample analysis
- Automated instrument QC to minimize user involvement and ensure instrument performance



The BD FACSVia is an easy and intuitive system that improves clinical laboratory workflow efficiency



Automated processes at the push of a button

- Automated instrument QC in less than 5 minutes
- Automated instrument setup and shutdown
- Intuitive user interface

Improved sample turnaround time (TAT)

- Simplified sample analysis with preloaded BD FACSVia HLA-B27 templates
- Easy access to data collection, analysis, and reporting functions, all in one screen
- Data files that can be exported in .fcs format for further analysis
- Improved sample throughput with the optional BD FACSVia™ Loader
- Optional BD FACSLink™ software for lab LIS connectivity helps minimize data entry transcription errors

HLA-B27 Kit

The presence of HLA-B27 antigen is strongly associated with ankylosing spondylitis (AS), a chronic inflammatory disease of the axial musculoskeletal system, and a few other rheumatic disorders (Reiter's syndrome, acute anterior uveitis, and inflammatory bowel disease).

HLA-B27 testing is routinely used to screen for AS since 90% of patients with AS have the HLA-B27 surface antigen compared to only 8% of healthy individuals

The BD™ HLA-B27 kit provides a qualitative two-color direct immunofluorescence method for the rapid detection of HLA-B27 antigen expression in erythrocyte-lysed whole blood (LWB).

HLA-B27 procedure

Principles of this procedure

- The Anti-HLA-B27 FITC/CD3 PE monoclonal antibody reagent is added to human whole blood
- The fluorochrome-labeled antibodies bind specifically to leucocyte surface antigens
- The stained samples are treated with BD FACSVia™ lysing solution to lyse erythrocytes
- The samples are washed and fixed before flow cytometric analysis


For information related to the cell suspension preparation, see the IFU for the BD HLA-B27 reagent kit.



The BD HLA-B27 kit is a CE-IVD reagent Kit

BD FACSVia clinical software with HLA-B27 predefined templates provide reliable results

HLA-B27



	Result
Total events	9808
CD3+ events	2239
CD3+ Percent of total events	22.83%
Decision Marker/Reagent Suffix	148
Sample Median	138
Conclusion	Negative

Ordering information

Description	Tests	Cat. No.
BD™ HLA-B27 Kit	50	340183

Class 1 Laser Product.
For In Vitro Diagnostic Use. CE-IVD. Not available in USA.
Trademarks are the property of their respective owners.
23-17590-00

BD Life Sciences, San Jose, CA, 95131, USA

bdbiosciences.com

